Phoenix Molecular Designs is pioneering the development of precise cancer therapeutics, focusing on the inhibition of Ribosomal S6 Kinases (RSK), particularly RSK2, which plays a critical role in the growth and metastasis of various cancers, including breast cancer. Their lead candidate, PMD-026, is a pan-RSK inhibitor that has shown promise in clinical trials, demonstrating the ability to halt tumor growth in a significant percentage of breast cancer patients. The company employs a biomarker-driven approach, utilizing RSK2 levels to identify patients who are most likely to benefit from their therapies, thereby enhancing the precision of cancer treatment.

The company is currently advancing PMD-026 through a Phase 2 clinical trial, known as Dauntless-1, which aims to evaluate the drug's efficacy in combination with fulvestrant for patients with metastatic HR+/HER2- breast cancer. This trial is particularly significant as it targets patients who have previously progressed on standard therapies, including CDK4/6 inhibitors. By focusing on RSK inhibition, Phoenix Molecular Designs is addressing a critical unmet need in cancer treatment, particularly for patients who exhibit resistance to existing therapies, and is positioned to lead the way in the development of innovative cancer treatments that are both effective and tailored to individual patient profiles.

United States

Phoenix Molecular Designs is a clinical-stage biotechnology company that is developing small molecule kinase inhibitors as a targeted therapy for cancer. 
 We are focused on treating one of the most aggressive types of breast cancer, Triple Negative Breast Cancer (TNBC), which currently has limited durable options.  Our patented cancer compounds position us in the lead to fast track our product to market as it fills an unmet medical need.  Our cancer therapy has the potential to save lives and improve quality of life.  

Phoenix Molecular Designs

Company Details